An essential step in the life cycle of the HIV-1 and HIV-2viruses is reverse transcription of the viral RNA genome to produce a double-stranded DNAcopy that is mediated by a virally encoded reverse transcriptase. establishing reverse transcriptase as a therapeutic target for intervention in the progression of AIDS1>2). The advent of resistance by the viruses to the available clinical compoundshas provided added impetus to the search and development of drug candidates that are more efficacious against the virus and that do not readily lead to the development of resistance.
In an attempt to find such clinical candidates we initiated screening of microbial extracts for inhibitors of HIV-1 reverse transcriptase. Our efforts resulted in the detection and isolation of two related novel chromodepsipeptides from a nocardioform actinomycete with indeterminant morphology. The compounds, which we have namedquinoxapeptin A and B, were structurally similar to luzopeptin A3~6) and sandriamycin7'8) the former of which was also active against HIV-1 and HIV-2 reverse transcriptase.
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Methods MA7095 (ATCC 55599) was isolated from a bark disc taken from a specimen of Betula papyrifera, at the Denali National Park in Alaska. The bark sample was lyophilized, homogenized and plated on a humic acid-based isolation medium9). The culture was isolated from this mediumand purified on yeast malt extract agar. A seed culture was produced by inoculating 50ml of aqueous medium in a 250ml triple baffled erlenmeyer flask with vegetative mycelia. The mediumcontained (in g/liter) glucose, 10; soluble starch, 20; yeast extract, 5; N-Z amine E, 5; CaCO3, 1; beef extract, 3; and Bacto-peptone, 5; in distilled water adjusted to pH 7.0 with NaOHprior to CaCO3addition and sterilization. Flasks were incubated at 28°C and shaken at 220rpm for 96 hours in order to obtain sufficientbiomass to inoculate the production medium. The production mediumwas inoculated by aseptic transfer of 2ml of seed culture to 44ml of production medium in a 250ml non-baffled erlenmeyer flask. The production medium contained (in g/liter) dextrin, 20; beta-cyclodextrin, 10; primary yeast, 10; tomato paste, 20; and CoCl2 à"6H2O, 0.005; in distilled water adjusted to pH 7.2 with NaOHprior to sterilization.
The production flasks were incubated at 28°C and shaken at 220rpm for 13 days prior to harvest. The contents of individual flasks were pooled and the active compounds were isolated and characterized as described10). 
Results

Chemotaxonomic Characteristics
The peptidoglycan of MA7095 contained mesodiaminopimelic acid. The whole cell sugars contained rhamnose, mannose and madurose in trace amounts. Major whole cell fatty acids are listed in Table 1 .
General Growth Characteristics
Good to excellent growth was observed on yeastextract malt -extract agar, sucrose -nitrate yeast extract agar, oatmeal agar and trypticase soy broth agar. Fair to moderate growth was observed on inorganic salts starch agar, tap water agar and Czapek's agar. Growth occurred at both 27 and 37°C.
Colony Morphology
Onyeast -malt agar at 21 days, the substrate mycelium was a grayish red-brown. Colonies were opaque, raised, with an entire edge and matte surface. The colonies were rubbery in texture and aerial mycelia were not observed.
Micromorphology
Substrate mycelia measured 0.76~l.14jum diameter and showed moderate branching. Aerial mycelia, when present, were scant and poorly developed without any spore bearing structures. Onsome media, small spherical vesicles (4-8/mi diameter) were found along the vegetative mycelia. On yeast malt extract agar these MAR. 1996 vesicles appearred to be pigmented.
Miscellaneous Physiological Reactions The culture did not produce H2Sin peptone -iron agar. Members of the genera Actinomadura, Microbispora, Microtetraspora, Geodermatophilus, Actinosynnema, Nocardiopsis, Saccharothrix and Streptoalloteichus all produce spore bearing structures under the conditions employed in these studies.
Fatty acid analysis can also be utilized to characterize actinomycetes in the absence of spore-bearing structures. To determine whether MA7095was a non-sporulating 
Inhibitor Isolation
The structures ofquinoxapeptin A and B are presented in Fig. 2 while the structure ofluzopeptin A is presented in Fig. 3 . Overall, there is a great deal of similarity between luzopeptin and the quinoxapeptins that comprise the basis of this report. Structurally, the quinoxapeptins contain the same peptide backbone but differ in the attached chromphores and the acyl substituent appended to the tetrahydropyrazidine-3-carboxylic residue. The isolation and structure determination of quinoxapeptin A and B are presented in a separate communication1 0).
Inhibitor Characterization Quinoxapeptin A and B were evaluated for inhibition of HIV-1 and HIV-2 RT and to assess their selectivity towards reverse transcriptase (Table 3) . Quinoxapeptin A inhibited HIV-1 and HIV-2 RT with IC50 values (the concentration of compound that elicits 50% inhibition) of 4 and 40nM, respectively.
Quinoxapeptin B was less potent and inhibited HIV-1 and HIV-2 RT with IC50 values of 10 and 100 nM, respectively while luzopeptin A inhibited HIV-1 and HIV-2 RT with IC50 values of 7 and 68 nM, respectively. Furthermore, Quinoxapeptin A HIV-1 and HIV-2 RT assays were performed as described20'21}.
Results are the mean of three separate experiments done in quadruplicate.
and B were not time-dependent inhibitors of either HIV-1 or HIV-2 RT. Wehave previously reported that rubromycin, another natural product inhibitor of HIV-1 RT, inhibited HIV-1 RTby competing with the template-primer substrate21}. To determine the mechanismof inhibition of quinoxapeptin Aa moredetailed kinetic analysis was performed.
The results of these studies (Figs. 4, 5 and Table 4) indicate that quinoxapeptin A was a non-competitive inhibitor of both HIV-1 and HIV-2 RT with Ki values of 18 and 22nM, respectively.
The almost identical indicated that acridine-like compounds inhibited HIV-1 RT in a similar manner. They also reported that doublereciprocal plots of kinetic data appeared to be mixed/ non-competitive in nature.
During the development of several non-nucleoside inhibitors of HIV-1 RT it became clear that the HIV-1 virus was developing resistance to the various compounds. In an attempt to understand this phenomenon, virus was isolated from infected individuals and the viral genome was sequenced. Several mutations were found in the RT coding region including changes in position 181 where a tyrosine was changed to a cysteine (Y181C, single letter amino acid code). Another isolate of the virus contained a substitution of asparagine for lysine at position 103 (K103N). A third variant included the double mutation (Y181C/K103N). The mutations map Kinetic analyses ofHIV-1 and HIV-2 RT were performed as described20). Results are from one experiment (performed in quadruplicate) and are representative of two other experiments. Kinetic data were analyzed using a computer program (Kcat, Princeton, NewJersey) to obtain the kinetic constants. to a region outside the primer-template and dNTP binding sites22).
Weexamined whether quinoxapeptin A was active against these three mutant forms of HIV-1RT and the results are presented in Table 5 . Quinoxapeptin A exhibits IC50 values of 12, 8 and 6nMagainst these three variant enzymes, respectively. This is only two-three fold less active than against the wild-type enzyme (IC50= 4nM, Table 3 ). The data suggest that the mode of inhibition of the mutant enzymes by quinoxapeptin A is probably different from that of the non-nucleoside inhibitors. This is consistent with the observed inhibition kinetics that indicate that that quinoxapeptin A may be interacting with the template-primer binding site.
To further examine the specificity of quinoxapeptin A it was tested against several mammalian DNA polymerases and the results are also presented in Tubes containing human HIV-1 (2nM) or HIV-2 RT (16 units) were incubated with either: (i) DMSO, (ii) 20.3 mMquinoxapeptin A (for HIV-1 RT) or (iii) 203 nM quinoxapeptin A (for HIV-2 RT) for 25 minutes at 31°C. Aliquots (10 jul) were removed and assayed directly (see Condition I of the table). The remainder of the three incubations were gel-filtered through 2.2 ml Sephadex G-25 columns equilibrated with 80mMTris, pH 8.2, 8 mMdithiothreitol, 0.14% bovine serum albumin abd 0.01% Triton X-100. The column eluates (25 jul), in column equilibration buffer, were tested for HIV-1 or HIV-2 RT activity as previously described21]. DMSOor quinoxapeptin A was added back to the assay tubes as shownabove. The data represent meanof quadruplicates for each condition from one experiment. specificity ofquinoxapeptin A for HIV-1 and HIV-2 RT. To examine whether quinoxapeptin A was a reversible inhibitor of HIV-1 and HIV-2 RT the experiment presented in Table 6 was performed. HIV-1 or HIV-2RT
was pre-incubated (separately) with either quinoxapeptin A or DMSO.Aliquots were removed for assay, while the remainder of the samples were passed through columns ofSephadex G-25. Testing of each sample before gel-filtration indicated that the HIV-1 and HIV-2 RT activity was inhibited by quinoxapeptin A (rows 2 and 8). Following gel-filtration, the control sample was inhibited by re-addition of quinoxapeptin A (rows 4 and 10). The HIV-1 and HIV-2 RT activity of the samples pre-incubated with quinoxapeptin A following gelfiltration was similar to the control sample suggesting that the inhibitors had dissociated from the enzyme (rows 5 and ll). Re-addition of quinoxapeptin A to these samples reduced HIV-1 and HIV-2 RT activity to the same degree as the control (rows 6 and 12). These data indicate that quinoxapeptin A is a reversible inhibitor of both HIV-1 and HIV-2 RT.
Discussion
The quinoxapeptins isolated from MA7095, while being novel, are structurally related to the luzopeptins described earlier3~6).
More recently, the isolation of sandriamycin, another chromodepsipeptide related to the luzopeptins has been described7?8). These compounds were both antibiotics and antitumorigenic3'7). However, there was no mention of whether these compoundswere effective as antivirals. In contrast to the previous data3'7), luzopeptin A and quinoxapeptin A were cytotoxic in a viral spread assay for the HIV-1 virus (results not shown). Reasons for this are unclear but mayinclude that the cell line used in these earlier studies was less sensitive to these compounds. Recently, the effect of one hundred and fifty-six compoundsisolated from natural product sources that were tested against HIV-1 and HIV-2 RT was described25). The most potent of these included fagaronine chloride and nitidine chloride that were equally active against both HIV-1 and HIV-2 RT (IC50 values of 20jUM25)). This is in contrast to quinoxapeptin A which is almost 5,000 times more active than either of these compounds against HIV-1 RT (Table 4) . These authors also speculated that these compounds were probably disrupting nucleic acid template functions25). The development of resistance to therapeutic agents by the HIV-1 virus is probably a function of viral mutation and the lack of fidelity of reverse transcriptase VOL.49 NO.3 THE JOURNAL OF ANTIBIOTICS activities26~28).
The discovery of quinoxapeptin A and B from microbial sources that are specific inhibitors of HIV-1 and HIV-2 RT as well as being active against three variants of HIV-1 RT is encouraging in that it validates the concept of screening natural product extracts for unique secondary metabolites that maybe used as potential drug development candidates.
